Pharmaceuticals

Asthma Therapeutics Market Outlook Indicating Growth Toward $47.87 Billion by 2030

March 18, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Asthma Therapeutics Market Over The Period 2026–2030?

The asthma therapeutics market has shown substantial growth over recent years. It is anticipated to expand from $33.11 billion in 2025 to $35.73 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.9%. This historical growth can be ascribed to several factors, including the limited availability of biologics, the reliance on short-acting beta agonists, the increasing global prevalence of asthma, a rise in hospital and specialty clinic visits, and the widespread adoption of oral and inhaled medications.

The asthma therapeutics market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $47.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. The anticipated growth during this period can be ascribed to several factors, including the advancement of innovative biologics and combination treatments, the expansion of telemedicine and digital health monitoring, increasing awareness regarding preventive treatments, improved healthcare accessibility in developing markets, and escalating investment in research and drug development. Key trends expected within the forecast timeframe encompass the increasing embrace of personalized asthma therapies, a surge in the utilization of inhalers and biologics, the proliferation of homecare and remote monitoring options, an escalating preference for combination inhalers, and a heightened emphasis on asthma care for both pediatric and geriatric populations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp

What Underlying Factors Are Accelerating The Growth Of The Asthma Therapeutics Market?

The rising occurrence of asthma is anticipated to drive the expansion of the asthma therapeutics market in the future. Asthma is a chronic illness characterized by inflammation and swelling in the airways, leading to their constriction, which impedes air transport from the nose and mouth to the lungs. This growing incidence of asthma is linked to an increase in pollutants, which irritate the airways and elevate the likelihood of developing the condition. Asthma treatments assist in managing the condition by regulating airway inflammation, alleviating symptoms, and averting asthma attacks. For example, as reported by the UK Parliament, a governmental body in the UK, in May 2025, approximately 3,886,879 individuals over six years old had been diagnosed with asthma in 2023-24, representing 6.5% of England’s population. Consequently, the rising occurrence of asthma is a key factor propelling the expansion of the asthma therapeutics market.

How Is The Asthma Therapeutics Market Divided Into Its Major Segments?

The asthma therapeutics market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)

2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications

3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:

1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide

2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol

3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast

4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline

5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab

6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

How Are Trends Transforming The Asthma Therapeutics Market Landscape?

Leading companies active in the asthma therapeutics market are prioritizing the development of inventive solutions, such as the anti-inflammatory rescue inhaler, to improve symptom alleviation, inflammation regulation, and holistic disease management. This particular type of inhaler represents a dual-action therapeutic strategy, integrating a fast-acting bronchodilator with an inhaled corticosteroid in a single device, thereby facilitating swift bronchodilation, immediate inflammation reduction, and the avoidance of severe asthma episodes. A notable instance occurred in January 2024, when AstraZeneca plc, a UK-based biopharmaceutical firm, unveiled AIRSUPRA, an FDA-approved anti-inflammatory rescue inhaler engineered to provide instant symptom relief concurrently with swift anti-inflammatory effects. It incorporates as-needed dual-mechanism dosing, offers real-time suppression of airway inflammation, and assists in averting lung-function deterioration linked to exacerbations. Ultimately, AIRSUPRA enhances asthma management, lessens the probability of severe attacks, and fortifies the overall efficacy of rescue therapy.

Who Are The Prominent Organizations Shaping The Asthma Therapeutics Market?

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mylan N.V.

Read the full asthma therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report

Which Region Is Projected To Dominate The Asthma Therapeutics Market During The Forecast Period?

North America was the largest region in the asthma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Asthma Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25702&type=smp

Browse Through More Reports Similar to the Global Asthma Therapeutics Market 2026, By The Business Research Company

Asthma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795